Related Experiment Video
Updated: Feb 4, 2026
03:47
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
1.2K
Heart Failure Outcomes With Volume-Guided Management.
John E Strobeck1, Jonathan Feldschuh2, Wayne L Miller3
1Heart-Lung Center, Hawthorne, New Jersey.
JACC. Heart Failure
|October 15, 2018
Summary
Quantitative blood volume analysis (BVA) guided heart failure (HF) therapy significantly reduced 30-day and 365-day mortality and readmissions compared to standard care. This approach improves outcomes for acute HF patients.
Area of Science:
- Cardiology
- Nephrology
- Internal Medicine
Background:
- Current heart failure (HF) management relies on clinical assessment for decongestion, lacking quantitative intravascular volume metrics.
- This gap highlights the need for advanced methods to guide HF treatment effectively.
Purpose of the Study:
- To evaluate the impact of quantitative blood volume analysis (BVA) on outcomes in acute heart failure (HF) patients.
- To compare the effectiveness of BVA-guided therapy against standard care using propensity-matched controls.
Main Methods:
- Retrospective analysis of 245 acute HF admissions (2007-2014) with mixed ejection fraction.
- Blood volume parameters (TBV, RBCV, PV) measured using iodine-131-labeled albumin.
- Decongestion targeted TBV thresholds; anemia treated based on cause; hematocrit monitored.
Main Results:
- 66% of subjects had plasma volume expansion, but only 37% were truly hypervolemic.
- 62% had true anemia (RBCV deficit).
- BVA-guided therapy showed significantly lower 30-day readmission (12.2% vs. 27.7%) and mortality (2.0% vs. 11.1%) rates compared to controls.
Conclusions:
- Blood volume analysis (BVA) offers a valuable tool for guiding volume management in acute heart failure.
- BVA-guided therapy demonstrated significant reductions in mortality and rehospitalization, supporting its clinical utility.
More Related Videos
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.0K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
9.1K
Related Concept Videos
01:30Heart Failure V: Medical Management
319
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319
01:29Heart Failure II: Pathophysiology
929
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
01:17Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
01:27Heart Failure I: Introduction
886
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
01:22Heart Failure VI: Adjunct Therapies
340
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
01:22Heart Failure Drugs: Diuretics
971
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971